Argomenti e Notizie
con raccolte
bibliografiche su
PubMed Logo
a cura del
Dott. C.Tarozzi
Anno 26°
Num. 148
Recens. 3000
Aderiamo allo standard HONcode per l'affidabilitŕ dell'informazione medica questo sito aderisce fin dal 2004 allo standard HONcode per l'affidabilità dell'informazione medica. Verifica qui.
Rassegna - Alimenti e Calcio - Questionari - T-Score - Valore di un Test - Calcolatori - Contatti - Digitalia - Radioactivity
Ricerca nell'archivio di questo sito...
Nuova bibliografia selezionata fino al mese di marzo 2021 (recensioni 19) Ordina per Autore - Titolo - Rivista
Agarwal A, Adachi JD.
Therapies for Preventing Bone Loss with Glucocorticoid Treatment.
Curr Osteoporos Rep. 2021 Feb;19(1):34-39.

Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A.
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review.
J Clin Med. 2021 Jan 4;10(1):152.

BĂ©gin MJ, Uebelhart B, Biver E, Ferrari S.
Ostéoporose - Nouvelle molécule, nouvelles directives [Osteoporosis: Novel drug, new recommendations].
Rev Med Suisse. 2021 Jan 13;17(720-1):63-67.

De Nigris F, Ruosi C, Colella G, Napoli C.
Epigenetic therapies of osteoporosis.
Bone. 2021 Jan;142:115680. doi: 10.1016/j.bone.2020.115680.

Estell EG, Rosen CJ.
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis.
Nat Rev Endocrinol. 2021 Jan;17(1):31-46.

Hardcastle SA.
Pregnancy and Lactation Associated Osteoporosis".
Calcif Tissue Int. 2021 Feb 23.

Haseltine KN, Chukir T, Smith PJ, Jacob JT, Bilezikian JP, Farooki A.
Bone Mineral Density: Clinical Relevance and Quantitative Assessment.
J Nucl Med. 2021 Apr;62(4):446-454.

Kanis JA, Harvey NC, Lorentzon M, Liu E, Vandenput L, McCloskey EV, Johansson H.
Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women.
Osteoporos Int. 2021 Jan;32(1):165-171.

Kendler DL, Adachi JD, Brown JP, Juby AG, Kovacs CS, Duperrouzel C, McTavish RK, Cameron C, Slatkovska L, Burke N.
A scorecard for osteoporosis in Canada and seven Canadian provinces.
Osteoporos Int. 2021 Jan;32(1):123-132.

Matsumoto T, Endo I.
RANKL as a target for the treatment of osteoporosis.
J Bone Miner Metab. 2021 Jan;39(1):91-105.

McLaughlin MB, Jialal I.
Calcitonin. 2020 Jul 26. In: StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2021 Jan–.

Oryan A, Sahvieh S.
Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
Life Sci. 2021 Jan 1;264:118681.

Romero-Díaz C, Duarte-Montero D, Gutiérrez-Romero SA, Mendivil CO.
Diabetes and Bone Fragility.
Diabetes Ther. 2021 Jan;12(1):71-86.

Rosenberg D, Avni T, Tsvetov G, Gafter-Gvili A, Diker-Cohen T.
Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
Osteoporos Int. 2021 Mar;32(3):413-424.

Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS.
Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis.
Support Care Cancer. 2021 May;29(5):2305-2317.

Tafaro L, Napoli N.
Current and Emerging Treatment of Osteoporosis.
2020 Aug 21. In: Falaschi P, Marsh D, editors. Orthogeriatrics: The Management of Older Patients with Fragility Fractures

Torregrosa JV, Ferreira AC, Cucchiari D, Ferreira A.
Bone Mineral Disease After Kidney Transplantation.
Calcif Tissue Int. 2021 Mar 25.

Yasuda H.
Discovery of the RANKL/RANK/OPG system.
J Bone Miner Metab. 2021 Jan;39(1):2-11.

Zhang C, Song C.
Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives.
Front Pharmacol. 2021 Jan 27;11:607017.

(Vers. 2.1)  Modificato il 31-3-2021   
questo sito aderisce ai principi HONCODE    disclaimer